Much of the federal government's efforts to buoy lagging childhood vaccination rates have been run through the Office of ...

Long-acting injectable HIV treatment leads to rectal shedding in a small proportion of patients with HIV, independent of the oral lead-in phase.

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Funds have also been suspended for AIDS Clinical Trial Group, a nearly 40-year-old system that has been responsible for key breakthroughs dating back to the first effective AIDS drug, AZT. All three ...

The trial will offer participants a new, twice-yearly injectable PrEP (pre-exposure prophylaxis) medicine called Lenacapivir.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV ...

Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Data from the last five years show that many people who contracted HIV had seen a provider in the year before.